Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein.
Humans
Antihypertensive Agents
/ pharmacology
SARS-CoV-2
Biological Products
/ pharmacology
COVID-19
COVID-19 Drug Treatment
Ligands
Quercetin
Spike Glycoprotein, Coronavirus
Molecular Dynamics Simulation
Peptide Hydrolases
Molecular Docking Simulation
Protease Inhibitors
/ pharmacology
Antiviral Agents
/ pharmacology
Rosmarinic Acid
SARS-CoV-2
main protease
molecular docking
molecular dynamics simulations
similarity search
spike protein
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
received:
15
09
2023
revised:
27
10
2023
accepted:
28
10
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
In this in silico study, we conducted an in-depth exploration of the potential of natural products and antihypertensive molecules that could serve as inhibitors targeting the key proteins of the SARS-CoV-2 virus: the main protease (Mpro) and the spike (S) protein. By utilizing Induced Fit Docking (IFD), we assessed the binding affinities of the molecules under study to these crucial viral components. To further comprehend the stability and molecular interactions of the "protein-ligand" complexes that derived from docking studies, we performed molecular dynamics (MD) simulations, shedding light on the molecular basis of potential drug candidates for COVID-19 treatment. Moreover, we employed Molecular Mechanics Generalized Born Surface Area (MM-GBSA) calculations on all "protein-ligand" complexes, underscoring the robust binding capabilities of rosmarinic acid, curcumin, and quercetin against Mpro, and salvianolic acid b, rosmarinic acid, and quercetin toward the S protein. Furthermore, in order to expand our search for potent inhibitors, we conducted a structure similarity analysis, using the Enalos Suite, based on the molecules that indicated the most favored results in the in silico studies. The Enalos Suite generated 115 structurally similar compounds to salvianolic acid, rosmarinic acid, and quercetin. These compounds underwent IFD calculations, leading to the identification of two salvianolic acid analogues that exhibited strong binding to all the examined binding sites in both proteins, showcasing their potential as multi-target inhibitors. These findings introduce exciting possibilities for the development of novel therapeutic agents aiming to effectively disrupt the SARS-CoV-2 virus lifecycle.
Identifiants
pubmed: 37958877
pii: ijms242115894
doi: 10.3390/ijms242115894
pmc: PMC10649947
pii:
doi:
Substances chimiques
Antihypertensive Agents
0
salvianolic acid
0
Biological Products
0
spike protein, SARS-CoV-2
0
Ligands
0
Quercetin
9IKM0I5T1E
Spike Glycoprotein, Coronavirus
0
Peptide Hydrolases
EC 3.4.-
Protease Inhibitors
0
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Science. 2020 Jun 19;368(6497):1331-1335
pubmed: 32321856
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32366720
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Phytochem Rev. 2022;21(1):291-312
pubmed: 34054380
Semin Cancer Biol. 2017 Oct;46:1-13
pubmed: 28511887
EClinicalMedicine. 2021 Jun 18;37:100962
pubmed: 34189447
Proteins. 2011 Oct;79(10):2794-812
pubmed: 21905107
Comput Biol Med. 2022 Jun;145:105452
pubmed: 35364308
Nutrition. 2021 Feb;82:111049
pubmed: 33290972
PLoS One. 2021 Mar 2;16(3):e0247548
pubmed: 33651840
Methods Mol Biol. 2018;1800:287-311
pubmed: 29934899
Mol Ther. 2022 Feb 2;30(2):963-974
pubmed: 34678509
J Mol Struct. 2021 Aug 5;1237:130380
pubmed: 33840835
J Comput Chem. 2003 Jun;24(8):920-30
pubmed: 12720312
Sci Rep. 2023 Apr 29;13(1):7055
pubmed: 37120654
Signal Transduct Target Ther. 2020 Oct 6;5(1):220
pubmed: 33024075
Eur J Pharmacol. 2021 Jan 5;890:173701
pubmed: 33130279
J Nat Prod. 2022 Jan 28;85(1):176-184
pubmed: 35007072
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149
pubmed: 32747721
Molecules. 2021 Jun 25;26(13):
pubmed: 34202374
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
Crit Care. 2020 Jul 31;24(1):475
pubmed: 32736573
J Med Virol. 2021 May;93(5):3143-3151
pubmed: 33580518
Br J Pharmacol. 2020 Nov;177(21):4825-4844
pubmed: 32333398
J Med Chem. 2006 Aug 10;49(16):4805-8
pubmed: 16884290
Expert Opin Ther Pat. 2013 Nov;23(11):1483-94
pubmed: 23968548
Curr Med Chem. 2020;27(38):6523-6535
pubmed: 32718281
Struct Chem. 2020;31(6):2487-2499
pubmed: 32837119
Eur J Med Chem. 2018 Jun 10;153:105-115
pubmed: 28923363
Food Chem. 2022 Mar 30;373(Pt B):131594
pubmed: 34838409
PLoS One. 2020 Oct 15;15(10):e0240653
pubmed: 33057452
Pharmaceuticals (Basel). 2022 Mar 03;15(3):
pubmed: 35337106
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
ACS Nano. 2020 Apr 28;14(4):5143-5147
pubmed: 32286790
ACS Infect Dis. 2021 Jun 11;7(6):1519-1534
pubmed: 33979123
Rev Bras Farmacogn. 2023;33(3):543-550
pubmed: 37151219
Phytother Res. 2021 Oct;35(10):5384-5396
pubmed: 34132421
RSC Adv. 2021 May 12;11(27):16711-16735
pubmed: 35479175
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Physiol Rev. 2018 Jul 1;98(3):1627-1738
pubmed: 29873596
Nature. 2020 Jun;582(7811):289-293
pubmed: 32272481
J Transl Med. 2022 Jul 14;20(1):314
pubmed: 35836239
Phytother Res. 2021 Jun;35(6):2841-2845
pubmed: 33448101
Phytomedicine. 2021 May;85:153310
pubmed: 32948420
Front Immunol. 2022 Aug 08;13:940756
pubmed: 36003396
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Virol. 2015 Sep;89(17):8816-27
pubmed: 26085157
Sci Rep. 2020 Aug 26;10(1):14214
pubmed: 32848162
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
RSC Adv. 2021 Sep 1;11(47):29267-29286
pubmed: 35492070
Mol Divers. 2023 Aug;27(4):1587-1602
pubmed: 35978064